KR20210135838A - Pd-1 variants with increased binding to pd-l1 - Google Patents

Abstract

The present invention relates to a PD-1 variant having increased binding force to PD-L1 and aglycosylation properties. The PD-1 variant of the present invention has significantly increased binding force to PD-L1 compared to a conventional PD-1 variant, and improves binding force and stability even though the PD-1 variant is an aglycosylated variant, so that the PD-1 variant can simultaneously overcome a problem of low binding force of PD-1 to PD-L1 and a problem of glycan heterogenity of protein remedies, thereby facilitating easy mass-production at low costs even from bacteria, and manufacturing biologics without problems according to a cell line, a culture process and a tableting process.

Description

PD-1 mutant with increased binding affinity to PD-L1 {PD-1 VARIANTS WITH INCREASED BINDING TO PD-L1}

The present invention relates to a PD-1 variant having increased binding affinity to PD-L1 and aglycosylation properties.

Pharmaceuticals for cancer treatment are largely divided into small molecule medicines and high molecular weight medicines, and high molecular weight medicines with specificity are attracting attention as therapeutic agents compared to small molecule medicines with relatively large side effects due to lack of specificity. Cancer cells express on the cell surface an immune checkpoint protein used when normal cells suppress immune cell activation in order to avoid the killing mechanism by immune cells. Research on checkpoint inhibitory proteins is being actively conducted.

Among immune checkpoint inhibitory proteins, it has been reported in academia that blocking PD-1/PD-L1 binding has a great effect on cancer treatment and has fewer side effects compared to other immune checkpoint inhibitory proteins (J. Naidoo et al. (J. Naidoo et al. (J. Naidoo et al. 2015) Annals of Oncology, Lucia Gelao et al. (2014) Toxins, Gorge K. Philips et al (2015) International Immunology). The PD-1 receptor is expressed on the surface of activated immune cell types, including T cells, B cells, natural killer (NK)/natural killer T (NKT) cells, etc. (Goodman, Patel & Kurzrock) , PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas, Nature Reviews Clinical Oncology, 14:203-220,2017.). PD-1 is a negative regulator of T cell activity, and the interaction of PD-1 with one of its ligands, PD-L1, on the tumor surface is an immune checkpoint that reduces the ability of activated T cells to generate an effective immune response. indicates blocking. High levels of expression of PD-L1 on the tumor cell surface enable escape from anti-tumor responses by inhibiting T cell functions, including cytotoxic activity. PD-L1 is overexpressed in many cancers and is often associated with poor prognosis (Okazaki T et al., Intern. Immun. 2007 19(7):813; Thompson RH et al., Cancer Res 2006, 66(7) ):3381). Interestingly, in contrast to T lymphocytes in normal tissues and peripheral blood T lymphocytes, the majority of tumor infiltrating T lymphocytes predominantly express PD-1, which is an antitumor with impaired upregulation of PD-1 on tumor-reactive T cells. suggest that it may contribute to the immune response (Blood 2009 114(8): 1537). This may be due to the utilization of PD-L1 signaling mediated by PD-L1-expressing tumor cells that interact with PD-1 expressing T cells, resulting in attenuation of T cell activation and evasion of immune surveillance (Sharpe et al. ., Nat Rev 2002, Keir ME et al., 2008 Annu. Rev. Immunol. 26:677). Thus, inhibition of the PD-L1/PD-1 interaction could enhance CD8+ T cell-mediated killing of tumors. Inhibition of PD-L1 signaling has been proposed as a means of enhancing T cell immunity in the treatment of cancer (e.g., tumor immunity) and infections, including both acute and chronic (e.g., persistent) infections. . Optimal therapeutic treatment may be combined with substances that block the PD-1 receptor/ligand interaction and directly inhibit tumor growth. There remains a need for optimal therapies for treating, stabilizing, preventing and/or delaying the onset of various cancers.

Therapeutic antibodies targeting PD-1 or PD-L1 block ligand-receptor interactions and restore immune function to the tumor microenvironment. The use of these mAbs has shown exciting clinical responses for many cancer types, and an increasing number of mAbs have entered clinical development. Several therapeutic monoclonal antibodies (mAbs) targeting PD-1 and PD-L1 are commercially available, and more than a dozen traditional and bispecific mAbs are being reviewed by the FDA and EMA. BMS' Opdivo (nivolumab), Merck's Keytruda (Pembrolizumab), Regeneron's Libtayo (Cemiplimab), which are anti-PD1 antibody therapeutics that inhibit PD-1 and PD-L1 binding, and Anti-PD-L1 antibody therapeutics Roche's Tecentriq (Atezolizumab), AstraZeneca's Imfinzi (Durvalumab), and Merck Sereno's Bavencio (Avelumab) have recently received US FDA approval, bringing innovation in the treatment of intractable cancer in clinical practice. The clinical demand for these PD-1/PD-L1 interaction inhibitory antibody therapeutics has exploded. Opdivo's 2018 sales were 7.5 billion US$ and Keytruda's 7.1 billion US$, ranking 4th and 6th in prescription drugs The clinical demand for these immune checkpoint inhibitory therapeutic antibodies is expected to expand further in the future.

However, since the antibody is a macromolecular protein with a molecular weight of 150,000, it is difficult to penetrate into the cancer tissue, making it difficult to inhibit the PD-1/PD-L1 binding of tumor cells and immune cells inside the cancer micro-environment. this exists For more effective treatment, the need for a protein therapeutic agent that is much smaller than an antibody and easily penetrates into the cancer tissue has emerged.

The PD-1 protein exposed as the extracellular domain (ectodomain) of human T cells is small in size and has the property of binding to the PD-L1 molecule expressed in tumors. is smaller than PD-L1, so PD-1, which has excellent cell penetration, is more suitable. However, wild-type PD-1 has a problem of binding to PD-L1 with very low affinity (equilibrium dissociation constant = ~8.7 μM).

On the other hand, immune checkpoint inhibitory antibody therapeutics such as Keytruda and Opdivo are administered after confirming the presence or absence of PD-L1 overexpression in cancer patients.

It is an object of the present invention to provide a PD-1 mutant having increased binding affinity to PD-L1.

It is also an object of the present invention to provide a binding inhibitor of PD-L1 and PD-1.

Another object of the present invention is to provide a composition for detecting PD-L1.

Another object of the present invention is to provide a pharmaceutical composition for the treatment or prevention of cancer.

Another object of the present invention is to provide a composition for diagnosing cancer.

It is also an object of the present invention to provide a method for specific detection of PD-L1.

In addition, it is an object of the present invention to provide a method for producing aglycosylated PD-1 having increased binding to PD-L1.

In order to achieve the above object, the present invention provides a PD-1 mutant with increased binding affinity to PD-L1.

In addition, the present invention provides a binding inhibitor of PD-L1 and PD-1 comprising the PD-1 mutant.

In addition, the present invention provides a composition for detecting PD-L1 comprising the PD-1 mutant.

In addition, the present invention provides a pharmaceutical composition for treating or preventing cancer comprising the PD-1 mutant.

In addition, the present invention provides a composition for diagnosing cancer comprising the PD-1 mutant.

In addition, the present invention provides a method for specific detection of PD-L1.

In addition, the present invention provides a method for producing aglycosylated PD-1 having increased binding affinity to PD-L1.

The PD-1 mutant of the present invention has significantly increased binding force with PD-L1 compared to the conventional PD-1 mutant, and although it is a glycosylated mutant, the binding force and stability are rather improved. It is possible to overcome the problem of low binding strength and glycan heterogenity of protein therapeutics at the same time, so it is easy to mass-produce at low cost even in bacteria, and it is possible to manufacture biologics without problems due to cell lines, culture process and purification process there is

1 is a diagram confirming the mutation site important for binding to PD-L1 in PD-1 mutant JY 101 by FACS.
2 is a diagram confirming the binding affinity of the aglycosylated PD-1 mutant Q_IITV with PD-L1.
3 is a diagram illustrating an SDS-PAGE gel photograph of a pMaz vector containing PD-L1-Fc and a purified PD-L1 dimer protein.
4 is a diagram confirming the activity of the fluorescently-labeled dimer PD-L1 by binding ability with PD-1 mutants.
5 is a diagram showing the amino acid sequence analysis data of the constructed error prone library.
6 is a view showing the library amplification (enrichment) test results through a flow cytometer.
7 is a diagram showing the results of analysis of PD-L1 binding force of E. coli cells displaying aglycosylated PD-1 mutants.
8 is a diagram showing an expression vector of aglycosylated PD-1 mutants, SDS-PAGE gel pictures and yields of purified aglycosylated PD-1 mutant proteins.
9 is a diagram showing sensorgrams for each concentration of each variant.
10 is a diagram showing _{the K D value of each variant.}
11 is a diagram showing sensorgrams for each concentration of HAC, which is a glycosylated variant, and Q12, which is a glycosylated variant, (JY_Q12).
12 is a diagram showing _{the K D} values of HAC, which is a glycosylated mutant, and Q12 (JY_Q12), which is a glycosylated mutant.

Hereinafter, the present invention will be described in detail as an embodiment of the present invention with reference to the accompanying drawings. However, the following embodiments are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted, and , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

In addition, the terms used in this specification are terms used to properly express the preferred embodiment of the present invention, which may vary according to the intention of a user or operator, or customs in the field to which the present invention belongs. Accordingly, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part "includes" a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.

All technical terms used in the present invention, unless otherwise defined, have the meaning as commonly understood by one of ordinary skill in the art of the present invention. In addition, although preferred methods and samples are described herein, similar or equivalent ones are also included in the scope of the present invention. The contents of all publications herein incorporated by reference are incorporated herein by reference.

Throughout this specification, common one-letter and three-letter codes for naturally occurring amino acids are used as well as generally accepted for other amino acids such as Aib (α-aminoisobutyric acid), Sar (N-methylglycine), etc. A three-character code is used. Amino acids referred to by abbreviation in the present invention are also described according to the IUPAC-IUB nomenclature as follows:

Alanine: A, Arginine: R, Asparagine: N, Aspartic Acid: D, Cysteine: C, Glutamic Acid: E, Glutamine: Q, Glycine: G, Histidine: H, Isoleucine: I, Leucine: L, Lysine: K, Methionine : M, phenylalanine: F, proline: P, serine: S, threonine: T, tryptophan: W, tyrosine: Y and valine: V.

In one aspect, the present invention provides an 8th, 9th, 13th, 25th, 31st, 32th, 33rd, 34th, 37th, 46th, 47th amino acid sequence of wild type PD-1 Any one or more selected from the group consisting of amino acids at the th, 50th, 52th, 69th, 87th, 88th, 90th, 92th, 96th, 100th, 108th, 128th, 138th and 140th amino acids The present invention relates to a mutant of programmed cell death protein-1 (PD-1), in which an amino acid is substituted with a sequence different from that of a wild-type amino acid, and which has enhanced binding to PD-L1 (programmed death-ligand 1).

In one embodiment, the amino acid of wild-type PD-1 may include the amino acid sequence of SEQ ID NO: 1, and the amino acid position may be based on the amino acid sequence of SEQ ID NO: 1.

In one embodiment, the PD-1 variants of the invention are W8L, N9D, F13I, S31G, F32L, S33P, N34R, E37K, M46I, S47G, T52M, C69T, V87D, R88G, R90Q, T96S, G100V, A108V, P128R , may include any one or more amino acid substitutions selected from the group consisting of P138S and G140C.

In one embodiment, the PD-1 variants of the invention are W8L, N9D, F13I, S31G, F32L, S33P, N34R, E37K, M46I, S47G, T52M, C69T, V87D, R88G, R90Q, T96S, G100V, A108V, P128R , may include any one or more amino acid substitutions selected from the group consisting of P138S and G140C, thereby increasing the binding force with PD-L1.

In one embodiment, the PD-1 variant of the present invention may comprise amino acid substitutions F13I, M46I, C69T and G100V, wherein W8L, N9D, N25Q, S31G, F32L, S33P, N34Q, N34R, E37K, S47G, It may further comprise any one or more amino acid substitutions selected from the group consisting of N50Q, T52M, V87D, R88G, R90Q, N92Q, T96S, A108V, P128R, P138S and G140C.

In one embodiment, the PD-1 variant of the present invention may further comprise amino acid substitutions N25Q, N34Q, N50Q and N92Q, thereby having aglycosylation properties.

In one embodiment, the PD-1 variants of the present invention may comprise amino acid substitutions F13I, N25Q, N34Q, M46I, N50Q, C69T, N92Q and G100V.

In one embodiment, the PD-1 variants of the invention may comprise amino acid substitutions F13I, N25Q, F32L, N34Q, M46I, N50Q, T52M, C69T, V87D, N92Q, T96S, G100V and A108V.

In one embodiment, a PD-1 variant of the invention may comprise amino acid substitutions W8L, N9D, F13I, N25Q, N34Q, E37K, M46I, N50Q, C69T, N92Q, G100V, A108V and G140C.

In one embodiment, the PD-1 variant of the present invention may comprise amino acid substitutions F13I, N25Q, S31G, F32L, S33P, N34Q, M46I, S47G, N50Q, T52M, C69T, N92Q, G100V, A108V, P128R and P138S. have.

In one embodiment, the PD-1 variants of the present invention may comprise amino acid substitutions F13I, N25Q, N34R, M46I, N50Q, C69T, R88G, R90Q, N92Q, G100V and A108V.

Because there is an N-linked glycosylation site present in the extracellular domain (ectodomain) of PD-1, there has been a problem of glycan heterogenity, which is a difference in glycosylation patterns depending on cell lines, culture processes, and purification processes. The PD-1 mutant of the present invention has significantly improved binding to PD-L1 by the amino acid substitution, compared to the existing variants, and has a glycosylation characteristic by specific amino acid substitution, so it is inexpensive and easy to mass-produce in bacteria. And there is no problem of glycation heterogeneity according to cell lines, culture process and purification process, so it has a great advantage in the manufacture of biopharmaceuticals. In addition, although N-glycosylation is very important for the binding ability of PD-1 protein to PD-L1 and protein stability, it is a glycosylated mutant with improved binding strength and stability.

The PD-1 variant of the present invention refers to a wild-type PD-1 protein (or peptide) in which some amino acid sequences are substituted,

As used herein, the term "variant" refers to a corresponding amino acid sequence comprising at least one amino acid difference (substitution, insertion or deletion) compared to a reference substance. In certain embodiments a “variant” has high amino acid sequence homology and/or conservative amino acid substitutions, deletions and/or insertions compared to a reference sequence. Also, as used herein, the term “PD-1 variant” refers to a PD-1 variant protein mutated in one or more amino acids to modulate its binding activity with PD-L1.

Specifically, the PD-1 variants of the present invention may be prepared by standard synthetic methods, recombinant expression systems, or any other method in the art. Thus, the peptides according to the invention can be synthesized in a number of ways, including, for example, those comprising:

(a) synthesizing peptides stepwise or by fragment assembly by means of solid or liquid phase methods, and isolating and purifying the final peptide product; or

(b) expressing a nucleic acid construct encoding the peptide in a host cell and recovering the expression product from the host cell culture; or

(c) performing cell-free in vitro expression of a nucleic acid construct encoding the peptide and recovering the expression product; or

A method for obtaining a fragment of a peptide by any combination of (a), (b) and (c), and then ligating the fragments to obtain a peptide, and recovering the peptide.

As a more specific example, through genetic manipulation, a gene encoding the PD-1 mutant of the present invention may be prepared, transformed into a host cell, and then expressed to produce the PD-1 mutant of the present invention.

In one aspect, the present invention relates to a nucleic acid molecule encoding the PD-1 variant of the present invention, a vector comprising the same, and a host cell comprising the vector.

As used herein, the term “nucleic acid molecule” refers to deoxyribonucleotides or ribonucleotides existing in single-stranded or double-stranded form, and includes natural nucleic acid analogues unless otherwise specified (Scheit, Nucleotide Analogs, John Wiley). , New York (1980); Uhlman and Peyman, Chemical Reviews, 90:543-584 (1990)).

As used herein, the term "vector" refers to any nucleic acid comprising a competent nucleotide sequence that is inserted into a host cell and recombined with and inserted into the host cell genome, or that replicates spontaneously as an episome. Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors, and the like.

As used herein, the term "host cell" refers to a eukaryotic or prokaryotic cell into which one or more DNA or vectors are introduced, and should be understood to refer not only to a specific target cell, but also to its progeny or potential progeny. In fact, the progeny are not identical to the parent cell as certain modifications may occur in subsequent generations due to mutations or environmental influences, but are still included within the scope of the term as used herein.

In one aspect, the present invention relates to a binding inhibitor of PD-L1 and PD-1 comprising the PD-1 variant of the present invention, a nucleic acid molecule thereof, or a vector comprising the same.

In one aspect, the present invention relates to a composition for detecting PD-L1, comprising the PD-1 variant of the present invention.

In one embodiment, the composition can detect and quantify the protein expression level of PD-L1.

In one embodiment, the PD-1 variant may be labeled with one selected from the group consisting of a chromogenic enzyme, a radioisotope, a chromopore, a luminescent material and a fluorescent material, and the fluorescent material is Cy (cyanine) series, It may be a Rhodamine-based, Alexa-based, BODIPY-based, or ROX-based fluorescent material, including Nile Red, BODIPY, 4,4-difluoro-4-bora-3a,4a. -diaza-s-indacene), cyanine, fluorescein, rhodamine, coumarin or Alexa.

Since the PD-1 mutant of the present invention can detect and quantify the expression level of PD-L1, it can be used before administration of conventional immune checkpoint inhibitory antibody therapeutics administered after confirming the presence or absence of PD-L1 overexpression in cancer patients. .

In one aspect, the present invention relates to a composition for bioimaging, comprising the PD-1 variant of the present invention.

In one aspect, the present invention relates to a pharmaceutical composition for treating or preventing cancer comprising the PD-1 mutant of the present invention, a nucleic acid molecule thereof, or a vector comprising the same.

In one embodiment, the cancer is brain tumor, melanoma, myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cervical cancer, ovarian cancer, colorectal cancer, Small intestine cancer, rectal cancer, fallopian tube carcinoma, perianal cancer, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, lymph gland cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, Soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brainstem glioma and It may be any one or more selected from the group consisting of pituitary adenoma.

The pharmaceutical composition of the present invention may be used as a single therapy, but may also be used in combination with other conventional biological therapy, chemotherapy or radiation therapy, and when such a combination therapy is performed, cancer can be treated more effectively. When the present invention is used for the prevention and treatment of cancer, chemotherapeutic agents that can be used together with the composition include cisplatin, carboplatin, procarbazine, mechlorethamine, Cyclophosphamide, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosourea, dactinomycin, daunoru daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide, tamoxifen, taxol, transpla Transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate and the like. Radiation therapy that can be used together with the composition of the present invention is X-ray irradiation and γ-ray irradiation.

In the present invention, the term "prevention" refers to any action that inhibits or delays the occurrence, spread, and recurrence of cancer by administration of the PD-1 mutant according to the present invention or a composition comprising the same.

The therapeutically effective amount of the composition of the present invention may vary depending on several factors, for example, the administration method, the target site, the condition of the patient, and the like. Therefore, when used in the human body, the dosage should be determined as an appropriate amount in consideration of both safety and efficiency. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. These considerations in determining effective amounts are found, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects, and the effective dose level is determined by the patient's Health status, disease type, severity, drug activity, sensitivity to drug, administration method, administration time, administration route and excretion rate, treatment period, factors including drugs used in combination or concurrently, and other factors well-known in the medical field can be determined according to The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.

The pharmaceutical composition of the present invention may include a carrier, diluent, excipient, or a combination of two or more commonly used in biological agents. As used herein, the term “pharmaceutically acceptable” means exhibiting non-toxic properties to normal cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, for example, Merck Index, 13th ed., Merck & Co. Inc. Compounds described in , saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components can be mixed and used, and if necessary, other antioxidants, buffers, bacteriostats, etc. Conventional additives may be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate into injectable formulations such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets. Furthermore, it can be preferably formulated according to each disease or component using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).

In one embodiment, the pharmaceutical composition may be one or more formulations selected from the group comprising oral formulations, topical formulations, suppositories, sterile injection solutions and sprays.

The compositions of the present invention may also include carriers, diluents, excipients or combinations of two or more commonly used in biological agents. The pharmaceutically acceptable carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, for example, Merck Index, 13th ed., Merck & Co. Inc. Compounds described in , saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components can be mixed and used, and if necessary, other antioxidants, buffers, bacteriostats, etc. Conventional additives may be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate into injectable formulations such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets. Furthermore, it can be preferably formulated according to each disease or component using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).

The composition of the present invention may further contain one or more active ingredients exhibiting the same or similar function. The composition of the present invention comprises 0.0001 to 10% by weight of the protein, preferably 0.001 to 1% by weight, based on the total weight of the composition.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive includes starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate. , lactose, mannitol, syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, lead carnauba, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, Calcium stearate, sucrose, dextrose, sorbitol and talc and the like can be used. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight based on the composition, but is not limited thereto.

The composition of the present invention may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) or orally according to a desired method, and the dosage may vary depending on the patient's weight, age, sex, health status, The range varies depending on the diet, administration time, administration method, excretion rate, and the severity of the disease. The daily dose of the composition according to the present invention is 0.0001 to 10 mg/ml, preferably 0.0001 to 5 mg/ml, and it is more preferable to divide and administer once to several times a day.

Liquid preparations for oral administration of the composition of the present invention include suspensions, internal solutions, emulsions, syrups, etc., and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. and the like may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.

In one aspect, the present invention relates to a composition for diagnosing cancer comprising the PD-1 mutant of the present invention.

As used herein, the term "detection" or "measurement" means to quantify the concentration of a detected or measured object.

In one aspect, the present invention relates to a cancer diagnosis kit comprising the composition for diagnosing cancer of the present invention.

In one embodiment, the kit may further include tools and/or reagents for collecting a biological sample from a subject or patient, as well as tools and/or reagents for preparing genomic DNA, cDNA, RNA or protein from the sample. have.

As used herein, the term “cancer diagnosis kit” refers to a kit including the cancer diagnosis composition of the present invention. Therefore, the expression “cancer diagnosis kit” can be used interchangeably or mixed with “cancer diagnosis composition”. As used herein, the term “diagnosis” refers to determining a subject's susceptibility to a specific disease or disorder, determining whether an object currently has a specific disease or disorder, or having a specific disease or disorder. Determining a subject's prognosis (e.g., identifying a pre-metastatic or metastatic cancer state, staging the cancer, or determining the responsiveness of the cancer to treatment), or therametrics (e.g., determining the efficacy of a treatment) monitoring the state of an object to provide information about it).

The PD-1 mutant of the present invention has anticancer activity through cancer cell death by immune cells by specifically binding with PD-L1, which is expressed by cancer cells to evade the killing mechanism by immune cells, with significantly increased binding force. , because it specifically binds to cancer cells, it can be used as a theranostic agent used in the diagnosis of cancer. In addition, instead of scFv, a chimeric antigen receptor (CAR)-T cell containing a PD-1 mutant can be produced and used as an anticancer agent, and can also be used as an anticancer adjuvant administered simultaneously, separately or sequentially with the anticancer agent. In addition, since it strongly binds to PD-L1 of cancer cells, it can be used as a drug delivery system targeting cancer cells.

In one aspect, the present invention provides a method comprising: contacting a biological sample isolated from a subject with a PD-1 variant of the present invention; determining the binding level of the PD-1 variant and PD-L1; And it relates to a method for providing information for cancer diagnosis, comprising the step of comparing the binding level of the PD-1 mutant and PD-L1 in a normal control sample.

In one embodiment, when the binding level of the PD-1 variant and PD-L1 in the biological sample isolated from the subject is higher than the binding level of the PD-1 variant and PD-L1 in the normal control sample, the test subject It may further include the step of determining that the cancer is.

As used herein, the term “sample (sample)” refers to a biological sample obtained from a subject or patient. Sources of biological samples may include fresh, frozen and/or preserved organ or tissue samples or solid tissue from biopsies or aspirates; blood or any blood component; The cells may be at any time of conception or development in a subject.

In one aspect, the present invention relates to a method for specific detection of PD-L1, comprising the steps of contacting a PD-1 mutant with a sample and detecting the binding of the PD-1 mutant to PD-L1.

In one aspect, the present invention provides a method comprising: culturing a host cell comprising a vector containing a nucleic acid molecule encoding a PD-1 variant of the present invention; and recovering the PD-1 mutant expressed by the host cell, to a method for producing aglycosylated PD-1 with increased binding affinity to PD-L1.

The present invention will be described in more detail through the following examples. However, the following examples are only for specifying the contents of the present invention, and the present invention is not limited thereto.

Example 1. Searching for major mutations in PD-1 that improve binding to PD-L1

The JY 101 mutant showing the highest binding affinity to PD-L1 discovered on the display system (mutant with mutations substituted with S1, I13, M17, P36, I46, T69, R79, V100, P114, L139 in wild-type PD-1) ), 10 mutations thereof were substituted one by one with amino acids of wild-type PD-1 (S1L, I13F, M17L, P36S, I46M, T69C, R79G, V100G, P114L and L139A). Specifically, the genome was amplified by the QuikChange PCR technique using the primers designed for this and Pfu turbo polymerase (Agilent). The amplified gene was transformed into Jude1 and the sequence was confirmed. Thereafter, JY 101 and its 10 variants (S1L, I13F, M17L, P36S, I46M, T69C, R79G, V100G, P114L and L139A) were treated in TB medium containing 2% glucose and 40 μg/ml of chloramphenicol, respectively. Incubated at ℃, 250 rpm for 16 hours. The cultured cells were inoculated in 6 ml of TB medium containing 40 μg/ml of chloramphenicol at a ratio of 1:50 _{, incubated to OD 600} = 0.5, cooled at 25°C and 250 rpm for 20 minutes, and 1 mM IPTG was added. to overexpress the protein at 25°C, 250 rpm, and 5 hours. E. coli overexpressed with protein was put into an e-tube by the same amount and centrifuged at 14,000 rpm for 1 minute to recover cells. In order to remove the residual medium, the cells in the e-tube were resuspended using 1 ml of 10 mM Tris-HCl (pH 8.0) and the washing process of centrifuging at 13,500 rpm for 1 minute was repeated twice. Cells were resuspended using 1 ml of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and the outer membrane was removed by rotation at 37° C. for 30 minutes. After collecting E. coli by centrifugation at 13,500 rpm for 1 minute, the supernatant was removed. The centrifuged E. coli was resuspended in 1 ml of Solution A [0.5 M sucrose, 20 mM MgCl2, 10 mM MOPS pH6.8] and centrifuged at 13,500 rpm for 1 minute. The centrifuged E. coli was resuspended by adding 1 ml of a solution of 1 ml of Solution A and 20 μl of 50 mg/ml lysozyme solution, followed by rotation at 37° C. for 15 minutes to remove the peptidoglycan layer. After centrifugation, the supernatant is removed, resuspended in 1 ml of PBS, 300 μl is taken, 700 μl of PBS and 3 nM tetrameric PD-L1-Alexa488 probe are added, and the spheroplast (spheroplast) is rotated at room temperature. ) was labeled with a fluorescent probe. After 1 hour of labeling, centrifugation was performed at 13,500 rpm for 1 minute, the supernatant was discarded, and the centrifuged E. coli was washed once with 1 ml of PBS and centrifuged again at 13,500 rpm for 1 minute. After centrifuged E. coli was resuspended in 1 ml of PBS, the change in binding force of each mutant was analyzed using Guava (Merck Millipore) equipment.

As a result, when the 13I, 46I, 69T, and 100V mutations were mutated to the wild type, binding force was significantly reduced, confirming that these four mutation positions are important for binding force with PD-L1 (Fig. One).

Example 2. Construction of aglycosylated variants

In order to construct a PD-1 mutant in which a mutation critical for improving binding affinity to PD-L1 is introduced and the N-glycosylation site is removed, 4 binding mutations (13I, 46I) of the JY 101 mutant identified in the above Examples , 69T and 100V), with a total of 4 (25N, 34N, 50N, 92N) N-glycosylation sites that are most similar to asparagine (N) and have a structure similar to that of asparagine (N), but glutamine (Q) that is not glycosylated ) was substituted with a new aglycosylation mutant Q_IITV (SEQ ID NO: 2) was prepared. Specifically, the genome of Q_IITV, a PD-1 variant having mutations of F13I, N25Q, N34Q, M46I, N50Q, C69T, N92Q and G100V, was synthesized (Genescript), and the synthesized genome was subjected to PCR using primers and Vent polymerase. After amplification, the amplified genome was treated with Sfi I enzyme. And ligated to Sfi I Sfi I-treated DNA to the treated pMopac12-NlpA-FLAG vector similarly to secrete proteins into the E. coli plasma membrane domain (periplasmic region) using the signal peptide of NlpA signal peptide to the immobilized cell lining of Lai pMopac12- The NlpA-PD1_Q_IITV-FLAG vector was constructed. Thereafter, a single clone was obtained by transformation into E. coli Jude1, and pMopac-12 vector insertion was confirmed through sequencing, thereby producing a glycosylated PD-1 mutant Q_IITV with improved binding to PD-L1. In order to verify the binding ability of the produced Q_IITV mutant to PD-L1, E. coli expressing wild-type PD-1, JY 101, and Q_IITV, respectively, was grown in TB medium containing 2% glucose and 40 μg/ml of chloramphenicol at 37° C., 250 Incubated at rpm for 16 hours. The cultured cells were inoculated in 6 ml of TB medium containing 40 μg/ml of chloramphenicol at a ratio of 1:50, _{incubated to OD 600} = 0.5, cooled at 25°C, 250 rpm for 20 minutes, and 1 mM IPTG was added to overexpress the protein at 25 °C, 250 rpm, for 5 hours. E. coli overexpressed with protein was put into an e-tube in the same amount and centrifuged at 14,000 rpm for 1 minute to recover cells. To remove the residual medium, the cells placed in the e-tube were resuspended using 1 ml of 10 mM Tris-HCl (pH 8.0) and washed twice by centrifugation at 13,500 rpm for 1 minute. Cells were resuspended using 1 ml of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution, and the outer membrane was removed by rotation at 37°C for 30 minutes, followed by 13,500 rpm for 1 minute. After collecting E. coli by centrifugation, the supernatant was removed. The centrifuged E. coli was resuspended in 1 ml of Solution A [0.5 M sucrose, 20 mM MgCl 2 , 10 mM MOPS pH6.8] and centrifuged at 13,500 rpm for 1 minute. 1 ml of a solution of Solution A and 20 μl of 50 mg/ml lysozyme solution was added to resuspend the centrifuged E. coli, and then rotated at 37° C. for 15 minutes to remove the peptidoglycan layer. After centrifugation, remove the supernatant, resuspend in 1 ml of PBS, take 300 μl, add 700 μl of PBS and 4 nM tetrameric PD-L1-Alexa488 probe, rotate at room temperature, and label the spheroplast with a fluorescent probe. did. After 1 hour of labeling, centrifugation was performed at 13,500 rpm for 1 minute, the supernatant was discarded, and the centrifuged E. coli was washed once with 1 ml of PBS and then centrifuged again at 13,500 rpm for 1 minute. After centrifuged E. coli was resuspended in 1 ml of PBS, binding to PD-L1 was analyzed using FACSCalibur (BD Biosciences) equipment, respectively.

As a result, it was confirmed that the Q_IITV mutant had a binding affinity to PD-L1 similar to that of JY 101 ( FIG. 2 ). Accordingly, a glycosylated mutant with improved binding to PD-L1 was engineered using the Q_IITV mutant as a template.

Example 3. Dimeric human PD-L1 (PD-L1-Fc) construction for screening aglycosylated PD-1 variants

3-1. PD-L1-Fc Cloning

In order to more efficiently screen aglycosylated PD-1 variants by increasing binding activity (Avidity), the Fc domain of antibody IgG is expressed in the C-terminal portion of PD-L1 to induce dimerization, and Fc and PD A GS linker was inserted between -L1 to ensure the fluidity of each protein. Specifically, PD-L1 and Fc genes were amplified using primers and Vent polymerase (New England Biolab), respectively, and then assembly PCR was performed using Vent polymerase. Each of the constructed genes was treated with Bss HII and Xba I (New England Biolab). The restriction enzyme-treated PD-L1-Fc gene was ligated into the same restriction enzyme-treated pMAZ vector. After transforming the ligated plasmid into Jude1 Escherichia coli, a single clone was obtained and it was confirmed that PD-L1-Fc was successfully inserted into the pMAZ vector through nucleotide sequence analysis.

3-2. Expression, purification and labeling of PD-L1-Fc

Expi293F cells were ^{subcultured in 300 ml at a density of 2x10 6} cells/ml, and one day later, the PD-L1-Fc expression vector prepared in Example 3-1 was transfected into Expi293F animal cells using PEI. The transfected cells were cultured for 7 days at 37 °C, 125 rpm, and 8% CO _{2 in a CO 2} shaker incubator, and then centrifuged to take only the supernatant. Then, it was equilibrated with 25x PBS and filtered through a 0.2 μm filter (Merck Millipore) using a bottle top filter. 1 ml of Protein A resin was added to the filtered culture solution, stirred at 4 °C for 16 hours, passed through a column to recover the resin, and then washed with 10 ml PBS. The washed resin was eluted with 100 mM glycine pH 2.7 buffer and then neutralized with 1M Tris-HCl pH 8.0 to obtain purified PD-L1 dimer protein (FIG. 3). The purified PD-L1 dimer protein was fluorescently labeled using the Alexa-488 labeling kit. In order to confirm the binding affinity of the fluorescently labeled dimer PD-L1, samples of wild-type PD-1, JY 101, and Q_IITV were used and analyzed in the same manner as in Example 2.

As a result, the signals of wild-type PD-1 and the JY 101 and Q_IITV mutants showed a similar pattern to that of the tetrameric PD-L1 (Fig. 2) (Fig. 4), indicating that the fluorescently labeled dimeric PD-L1 was active. was able to confirm

Example 4. Production of large PD-1 error prone library for using ultra-fast screening technique

To search for ladybird screen PD-1 variants exhibit PD-L1 with high affinity at a high speed, pMopac12-NlpA-PD-1_Q_IITV -FLAG based on a PD-1_Q_IITV Sfi I site of both to an error into all parts of the A primer comprising a was designed. The genome was amplified by Error Prone PCR using the designed primers, Taq Polymerase (TAKARA), dNTPs (Invitrogen), MgCl2, MnCl2 (SIGMA), etc. The amplified genome was converted to Sfi I. Enzyme treatment and Sfi I After inserting into the enzyme-treated pMopac12-NlpA-FLAG vector and ligation, the cells were transformed into Jude1 cells. After the transformed E. coli was spread on a square plate and cultured at 37° C. for 16 hours, E. coli was recovered with TB containing 2% glucose to obtain an initial library ( FIG. 5 ).

Example 5. Screening of aglycosylated PD-1 variants

After adding 40 μg/ml of chloramphenicol to 25 ml of TB medium containing 2% glucose, the library prepared in Example 4 was inoculated into a 250 mL flask, incubated at 37° C. and 250 rpm for 4 hours, and then 40 μg E. coli cultured in 100 ml of TB medium containing /ml of chloramphenicol was inoculated at a ratio of 1:100. After incubation to OD ₆₀₀ = 0.5, after cooling at 25 °C and 250 rpm for 20 minutes, 1 mM IPTG was added to overexpress the protein at 25 °C, 250 rpm, 5 hours, and centrifuged at 14000 rpm for 1 minute to centrifuge the cells. recovered. To remove the residual medium, the cells placed in the e-tube were resuspended using 1 ml of 10 mM Tris-HCl (pH 8.0) and washed twice by centrifugation at 13,500 RPM for 1 minute. Cells were resuspended in 1 ml of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] solution and rotated at 37° C. for 30 minutes to remove the outer cell membrane. E. coli was obtained by centrifugation at 13,500 rpm for 1 minute, and the supernatant was removed. The centrifuged E. coli was resuspended in 1 ml of Solution A [0.5 M sucrose, 20 mM MgCl ₂ , 10 mM MOPS pH6.8] and centrifuged at 13,500 rpm for 1 minute. 1 ml of a solution of 1 ml of Solution A and 20 μl of 50 mg/ml lysozyme solution was added to resuspend the centrifuged E. coli, and then rotated at 37° C. for 15 minutes to remove the peptidoglycan layer. After centrifugation, remove the supernatant, resuspend in 1 ml of PBS, take 300 μl, add 700 μl of PBS and 25 nM dimeric PD-L1-Alexa488 probe, rotate at room temperature to label the fluorescent probe on spheroplasts. did. After the labeling process was performed for 1 hour, the E. coli obtained by centrifugation at 13,500 rpm for 1 minute and discarding the supernatant was washed once with 1 ml of PBS and then centrifuged again at 13,500 rpm for 1 minute. After resuspending the centrifuged E. coli in 1 ml PBS, E. coli having high binding affinity to PD-L1 was recovered using an S3 sorter (Bio-Rad) equipment. The recovered E. coli genes were obtained through PCR amplification using primers, and the obtained genomes were treated with sfi I restriction enzyme and ligated into the restriction enzyme-treated pMopac12-NlpA-FLAG vector. After transforming each plasmid into Jude1, Escherichia coli was spread on a square plate, incubated at 37° C. for 16 hours, and recovered and stored frozen. The above screening process was further repeated 4 times (round).

Example 6. Confirmation of amplification of PD-L1 affinity-increasing aglycosylated PD-1 variants

After adding 40 μg/ml of chloramphenicol to 25 ml of TB containing 2% glucose, the Initial library of Example 5 (library prepared in Example 4), Round 1 library, Round 2 library, 3 The round library, round 4 library, and round 5 library were each placed in a 250 mL flask. After incubation for 4 hours at 37° C. and 250 rpm, the cultured E. coli was inoculated 1:100 into 100 ml of TB containing 40 μg/ml of chloramphenicol. After culturing E. coli to OD ₆₀₀ = 0.5, the protein was overexpressed at 25 °C and 250 rpm for 5 hours by cooling at 25 °C and 250 rpm for 20 minutes and adding 1 mM IPTG. In addition, wild-type PD-1 and HAC-V-PD-1 cells were each inoculated for use as a control, and incubated at 37° C. and 250 rpm for 16 hours. The cultured cells were inoculated 1:50 in 6 ml of TB medium containing 40 μg/ml of chloramphenicol and _{cultured to OD 600} =0.5, followed by overexpression of the protein. Each E. coli was put in an e-tube in the same amount, and the cells were recovered by centrifugation at 14,000 rpm for 1 minute. To remove the residual medium, the cells placed in the e-tube were resuspended using 1 ml of 10 mM Tris-HCl (pH 8.0) and washed twice by centrifugation at 13,500 rpm for 1 minute. The cells were resuspended in 1 ml of STE [0.5 M sucrose, 10 mM Tris-HCl, 10 mM EDTA (pH 8.0)] and rotated at 37° C. for 30 minutes to remove the outer cell membrane. After collecting E. coli by centrifugation at 13,500 rpm for 1 minute, the supernatant was removed. The centrifuged E. coli was resuspended in 1 ml of Solution A [0.5 M sucrose, 20 mM MgCl ₂ , 10 mM MOPS pH6.8] and centrifuged at 13500 rpm for 1 minute. 1 ml of a solution of 1 ml of Solution A and 20 μl of 50 mg/ml lysozyme solution was added to resuspend the centrifuged E. coli, and then rotated at 37° C. for 15 minutes to remove the peptidoglycan layer. After centrifugation, remove the supernatant, resuspend in 1 ml of PBS, take 300 μl, add 700 μl of PBS and 3 nM dimeric PD-L1-Alexa488 probe, rotate at room temperature, and label the fluorescent probe on spheroplasts. did. After labeling for 1 hour, centrifugation was performed at 13,500 rpm for 1 minute. The supernatant was discarded and the centrifuged E. coli was washed once with 1 ml of PBS and then centrifuged again at 13,500 rpm for 1 minute. After resuspending the centrifuged E. coli in 1 ml of PBS, the binding force with PD-L1 was analyzed by measuring the fluorescence signal value (Mean fluorescence intensity, MFI) using a flow cytometer (Calibur, BD Biosciences).

As a result, as the screening progressed, it was confirmed that variants with high binding affinity to PD-L1 were amplified in the library ( FIG. 6 ).

Example 7. Securing aglycosylated PD-1 mutants with improved PD-L1 binding affinity

After culturing single colonies of the last round as in the above examples, overexpressing the protein and recovering E. coli, respectively, removing the peptidoglycan layer and fluorescently labeling spheroplasts, using FACSCalibur equipment to PD-L1 The binding force with the fluorescence signal was analyzed by measuring the value of the fluorescence signal. As a result, Q10 (F13I, N25Q, F32L, N34Q, M46I, N50Q, T52M, C69T, V87D, N92Q, T96S, G100V, A108V) (SEQ ID NO: 3), Q12 (W8L, N9D, F13I, N25Q, N34Q, E37K) , M46I, N50Q, C69T, N92Q, G100V, A108V, G140C) (SEQ ID NO: 4), Q18 (F13I, N25Q, S31G, F32L, S33P, N34Q, M46I, S47G, N50Q, T52M, C69T, N92Q, G100V, A108V , P128R, P138S) (SEQ ID NO: 5) and Q33 (F13I, N25Q, N34R, M46I, N50Q, C69T, R88G, R90Q, N92Q, G100V, A108V) variants of (SEQ ID NO: 6) have high binding affinity to PD-L1 It was found that it was selected (FIG. 7).

Example 8. Expression and purification of variants with improved PD-L1 binding affinity

The top four aglycosylated PD-1 mutants (Q10, Q12, Q18 and Q33), which were shown to have high binding affinity to PD-L1 in Example 7, were expressed and purified in animal cells and then cloning was performed to verify their binding affinity. proceeded. For this purpose, the genes of wild-type Q_PD1 in which all N-glycosylation positions of wild-type PD-1 were changed to Q, the control AHAC, and the mutants Q_IITV, Q10, Q12, Q18 and Q33 discovered in the present invention were PCR using primers and Vent polymerase was amplified with The amplified genome was treated with Bss HII and Xba I enzymes and ligated to pMAZ vector, a vector for expression of animal cells treated with the same enzyme, respectively. The ligated plasmid was transformed into Jude1 Escherichia coli, and the sequence was confirmed through individual colony analysis. The produced vector for expression of the PD-1 variant (pMAZ-PD1 Q_WT-His tag, pMAZ-PD1 AHAC-His tag, pMAZ-PD1 Q_IITV-His tag, pMAZ-PD1 Q10-His tag, pMAZ-PD1 Q12-His tag, pMAZ-PD1 Q18-His tag and pMAZ-PD1 Q33-His tag) were transfected into Expi293F animal cells using PEI, respectively. After that, it was incubated for 7 days at 37 ° C., 125 rpm and 8% CO _{2 in a CO 2} shaker incubator, followed by centrifugation to take only the supernatant. Then equilibrated with 25x PBS. After filtering with a 0.2 μm filter (Merck Millipore) using a bottle top filter, 0.5 ml of Ni-NTA resin was added to the filtered culture medium, stirred at 4° C. for 16 hours, and then the resin was recovered by flowing through the column. The recovered resin was washed with a PBS solution containing 10 CV (column volume) of 10 mM imidazole (Sigma), and then washed once again with 10 CV of a PBS solution containing 20 mM imidazole. After eluting with a PBS solution containing 250 mM imidazole, the buffer was changed using centrifugal filter units 3K (Merck Millipore). Thereafter, the expressed and purified aglycosylated PD-1 mutant proteins were confirmed by SDS-PAGE gel.

As a result, wild-type Q_PD-1 was not expressed, and the yield of the AHAC mutant as a control was very low, whereas the mutants discovered in the present invention had increased stability despite the absence of glycosylation, and obtained with high purity and yield. could (Fig. 8).

Example 9. Determination of binding affinity of aglycosylated PD-1 variants

CKJ 49 (F13L/N25D/C69S/N92S/R137K), JY 101 (N1S/F13I/L17M/S36P/M46I/C69T/G79R/G100V/L114P/A139L), and The binding affinity of the aglycosylated PD-1 mutants (Q10, Q12, Q18 and Q33) discovered in the present invention to PD-L1 was measured. Specifically, the AR2G biosensor (Pall Fortebio) was first activated with 20 mM EDC and 10 mM s-NHS for 5 minutes, then 20 μg/ml of PD-L1-streptavidin was immobilized for 5 minutes, and then 5 with 1 M ethanolamine. It was quenched for minutes. After holding the baseline (baseline) for 30 seconds with 1X kinetic buffer, 1000 nM, 500 nM, 250 nM and 125 nM PD-1 variants were combined for 1 minute (association), 1X kinetic buffer for 60 seconds dissociation by flow. As a result of analyzing the sensorgram for each concentration of each variant in this way ( FIG. 9 ), and analyzing the final K _D value, it was found that the binding force of Q12 to PD-L1 was the highest ( FIG. 10 ).

Example 10. Comparison of binding affinity to PD-L1 of the discovered aglycosylated PD-1 mutant (JY_Q12) and the existing glycosylated PD-1 mutant (HAC)

In the case of PD-1, since glycosylation is very important for PD-L1 binding, and non-glycosylated PD-1 almost loses PD-L1 binding, the aglycosylated PD-1 mutant discovered in the present invention and the binding ability of the glycosylated PD-1 mutant to PD-L1 was comparatively analyzed. To this end, through Biolayer interferometry assay (BLItz, Pall Fortebio), HAC, which is a glycated PD-1 mutant known in previous studies, and the aglycosylated mutant JY_Q12 (Q12) showing the highest binding affinity in Example 9 to PD-L1 was measured. Specifically, as in the above example, the AR2G biosensor (Pall Fortebio) was first activated with 20 mM EDC and 10 mM s-NHS for 5 minutes, and then 20 μg/ml of PD-L1-streptavidin was immobilized for 5 minutes. Then, it was quenched with 1 M ethanolamine for 5 minutes. After holding the baseline (baseline) for 30 seconds with 1X kinetic buffer, 1000 nM, 500 nM, 250 nM, 125 nM and 62.5 nM of PD-1 variants were bound for 1 minute, and 1X kinetic buffer was added for 60 seconds. spilled and dissociated. In this way, the sensorgrams for each concentration of each variant were analyzed ( FIG. 11 ), and the final K _D value was analyzed ( FIG. 12 ).

As a result, the aglycosylated PD-1 mutant Q12 (JY_Q12) discovered in the present invention exhibited a PD-L1 binding force almost similar to that of the conventional glycated PD-1 mutant (HAC) ( FIGS. 11 and 12 ). Through this, it can be confirmed that the aglycosylated mutant of the present invention has significantly improved binding force to a similar degree to the glycosylated mutant without glycosylation, which is important for binding force to PD-L1, and since it is a glycosylated form, it can be produced in bacteria, and in animal cells It can be seen that there is no problem of glycan heterogeneity during production, and the problem of non-specific receptor binding according to glycation can be solved for various purposes such as treatment and diagnosis.

<110> Korea University Research and Business Foundation <120> PD-1 VARIANTS WITH INCREASED BINDING TO PD-L1 <130> DP-2020-0218 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> WT PD-1 <400> 1 Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser Phe 20 25 30 Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro 35 40 45 Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn Asp Ser Gly Thr 85 90 95 Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln 130 135 140 <210> 2 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> JY_Q_IITV <400> 2 Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Ile Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Gln Ala Thr Phe Thr Cys Ser Phe 20 25 30 Ser Gln Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Ile Ser Pro 35 40 45 Ser Gln Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Thr Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Val Arg Ala Arg Arg Gln Asp Ser Gly Thr 85 90 95 Tyr Leu Cys Val Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln 130 135 140 <210> 3 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> JY_Q10 <400> 3 Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Ile Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Gln Ala Thr Phe Thr Cys Ser Leu 20 25 30 Ser Gln Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Ile Ser Pro 35 40 45 Ser Gln Gln Met Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Thr Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Asp Arg Ala Arg Arg Gln Asp Ser Gly Ser 85 90 95 Tyr Leu Cys Val Ala Ile Ser Leu Ala Pro Lys Val Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln 130 135 140 <210> 4 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> JY_Q12 <400> 4 Leu Asp Ser Pro Asp Arg Pro Leu Asp Pro Pro Thr Ile Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Gln Ala Thr Phe Thr Cys Ser Phe 20 25 30 Ser Gln Thr Ser Lys Ser Phe Val Leu Asn Trp Tyr Arg Ile Ser Pro 35 40 45 Ser Gln Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Thr Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Val Arg Ala Arg Arg Gln Asp Ser Gly Thr 85 90 95 Tyr Leu Cys Val Ala Ile Ser Leu Ala Pro Lys Val Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Cys Gln Phe Gln 130 135 140 <210> 5 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> JY_Q18 <400> 5 Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Ile Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Gln Ala Thr Phe Thr Cys Gly Leu 20 25 30 Pro Gln Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Ile Gly Pro 35 40 45 Ser Gln Gln Met Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Thr Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Val Arg Ala Arg Arg Gln Asp Ser Gly Thr 85 90 95 Tyr Leu Cys Val Ala Ile Ser Leu Ala Pro Lys Val Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Arg 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Ser Ala Gly Gln Phe Gln 130 135 140 <210> 6 <211> 143 <212> PRT <213> Artificial Sequence <220> <223> JY_Q33 <400> 6 Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Ile Ser Pro Ala 1 5 10 15 Leu Leu Val Val Thr Glu Gly Asp Gln Ala Thr Phe Thr Cys Ser Phe 20 25 30 Ser Arg Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Ile Ser Pro 35 40 45 Ser Gln Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln 50 55 60 Pro Gly Gln Asp Thr Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg 65 70 75 80 Asp Phe His Met Ser Val Val Gly Ala Gln Arg Gln Asp Ser Gly Thr 85 90 95 Tyr Leu Cys Val Ala Ile Ser Leu Ala Pro Lys Val Gln Ile Lys Glu 100 105 110 Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro 115 120 125 Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln 130 135 140

Claims (24)

8th, 9th, 13th, 25th, 31st, 32th, 33rd, 34th, 37th, 46th, 47th, 50th, 52th in the amino acid sequence of wild type PD-1 , 69th, 87th, 88th, 90th, 92th, 96th, 100th, 108th, 128th, 138th, and any one or more amino acids selected from the group consisting of the 140th amino acid is different from the wild-type amino acid A mutant of Programmed cell death protein-1 (PD-1) with increased binding affinity to PD-L1 (Programmed death-ligand 1) substituted with the sequence. The PD-1 mutant of claim 1, wherein the amino acid of wild-type PD-1 comprises the amino acid sequence of SEQ ID NO: 1. 2. The group of claim 1, comprising: W8L, N9D, F13I, S31G, F32L, S33P, N34R, E37K, M46I, S47G, T52M, C69T, V87D, R88G, R90Q, T96S, G100V, A108V, P128R, P138S and G140C. A PD-1 variant with increased binding affinity to PD-L1, comprising any one or more amino acid substitutions selected from. The PD-1 mutant with increased binding affinity to PD-L1 according to claim 1, comprising amino acid substitutions F13I, M46I, C69T and G100V. 5. The group of claim 4, consisting of W8L, N9D, N25Q, S31G, F32L, S33P, N34Q, N34R, E37K, S47G, N50Q, T52M, V87D, R88G, R90Q, N92Q, T96S, A108V, P128R, P138S and G140C. A PD-1 variant with increased binding affinity to PD-L1, further comprising any one or more amino acid substitutions selected from. The PD-1 variant with enhanced binding affinity to PD-L1 according to claim 1, further comprising amino acid substitutions N25Q, N34Q, N50Q and N92Q. According to claim 6, wherein the aglycosylated (aglycosylated) variant, PD-1 mutant with increased binding affinity to PD-L1. The PD-1 mutant with enhanced binding affinity to PD-L1 according to claim 1, comprising amino acid substitutions F13I, N25Q, N34Q, M46I, N50Q, C69T, N92Q and G100V. The PD-1 variant with enhanced binding affinity to PD-L1 according to claim 1, comprising amino acid substitutions F13I, N25Q, F32L, N34Q, M46I, N50Q, T52M, C69T, V87D, N92Q, T96S, G100V and A108V. . According to claim 1, wherein the amino acid substitutions W8L, N9D, F13I, N25Q, N34Q, E37K, M46I, N50Q, C69T, N92Q, G100V, A108V and G140C, the PD-1 variant with increased binding affinity to PD-L1, comprising: . The binding affinity to PD-L1 according to claim 1, comprising amino acid substitutions F13I, N25Q, S31G, F32L, S33P, N34Q, M46I, S47G, N50Q, T52M, C69T, N92Q, G100V, A108V, P128R and P138S. Enhanced PD-1 variants. The PD-1 variant with enhanced binding affinity to PD-L1 according to claim 1, comprising amino acid substitutions F13I, N25Q, N34R, M46I, N50Q, C69T, R88G, R90Q, N92Q, G100V and A108V. A nucleic acid molecule encoding the PD-1 variant of claim 1. A vector comprising the nucleic acid molecule of claim 13 . A host cell comprising the vector of claim 14 . A binding inhibitor of PD-L1 and PD-1 comprising the PD-1 variant of claim 1, the nucleic acid molecule of claim 13, or the vector of claim 14. A composition for detecting PD-L1, comprising the PD-1 variant of claim 1. The composition for detecting PD-L1 according to claim 17, wherein the PD-1 variant is labeled with one selected from the group consisting of a chromogenic enzyme, a radioactive isotope, a chromopore, a luminescent material, and a fluorescent material. A pharmaceutical composition for treating or preventing cancer comprising the PD-1 variant of claim 1, the nucleic acid molecule of claim 13, or the vector of claim 14 as an active ingredient. 20. The cancer of claim 19, wherein the cancer is brain tumor, melanoma, myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cervical cancer, ovarian cancer, colorectal cancer , small intestine cancer, rectal cancer, fallopian tube carcinoma, perianal cancer, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, lymph gland cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer , soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, renal or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brainstem glioma And any one or more selected from the group consisting of pituitary adenoma, a pharmaceutical composition for the treatment or prevention of cancer. A composition for diagnosing cancer comprising the PD-1 mutant of claim 1. a) contacting the biological sample isolated from the subject with the PD-1 variant of claim 1;
b) determining the binding level of the PD-1 variant and PD-L1; and
c) Comprising the step of comparing the binding level of the PD-1 mutant and PD-L1 in a normal control sample, an information providing method for cancer diagnosis. A method for specific detection of PD-L1 comprising the steps of contacting the PD-1 mutant of claim 1 with a sample and detecting the binding of the PD-1 mutant to PD-L1. a) culturing a host cell containing a vector containing a nucleic acid molecule encoding the PD-1 variant of claim 1; and
b) A method for producing aglycosylated PD-1 with increased binding affinity to PD-L1, comprising the step of recovering the PD-1 mutant expressed by the host cell.

Images